Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.
Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer.
复制标题
Tetraspanin 6是结直肠癌发生的调节因子。
DOI:
10.1073/pnas.2011411118
复制
发表时间:
2021-09-28
影响因子:
11.1
通讯作者:
Berditchevski F
中科院分区:
文献类型:
--
作者:
Andrijes R;Hejmadi RK;Pugh M;Rajesh S;Novitskaya V;Ibrahim M;Overduin M;Tselepis C;Middleton GW;Győrffy B;Beggs AD;Berditchevski F
Tetraspanin protein (Tspan6) is a member of the tetraspanin family. Using a combination of in vitro and in vivo assays, we demonstrate that Tspan6 functions as a tumor suppressor in colorectal cancer (CRC) by attenuating the epidermal growth factor receptor (EGFR)–based signaling axis. Tspan6 forms a tripartite complex with transmembrane form of TGF-α and an adaptor protein syntenin-1 and negatively regulates secretion of TGF-α. The expression of Tspan6 is frequently decreased in CRC, and this correlates with poor survival. Importantly, the expression of Tspan6 in CRC correlated independently of tumor molecular profile with better patient responses to Cetuximab, an EGFR-targeted therapy. These results identify Tspan6 as a regulator of CRC development and a potential predictive biomarker for EGFR-targeted therapies. Early stages of colorectal cancer (CRC) development are characterized by a complex rewiring of transcriptional networks resulting in changes in the expression of multiple genes. Here, we demonstrate that the deletion of a poorly studied tetraspanin protein Tspan6 in Apcmin/+ mice, a well-established model for premalignant CRC, resulted in increased incidence of adenoma formation and tumor size. We demonstrate that the effect of Tspan6 deletion results in the activation of EGF-dependent signaling pathways through increased production of the transmembrane form of TGF-α (tmTGF-α) associated with extracellular vesicles. This pathway is modulated by an adaptor protein syntenin-1, which physically links Tspan6 and tmTGF-α. In support of this, the expression of Tspan6 is frequently decreased or lost in CRC, and this correlates with poor survival. Furthermore, the analysis of samples from the epidermal growth factor receptor (EGFR)–targeting clinical trial (COIN trial) has shown that the expression of Tspan6 in CRC correlated with better patient responses to EGFR-targeted therapy involving Cetuximab. Importantly, Tspan6-positive patients with tumors in the proximal colon (right-sided) and those with KRAS mutations had a better response to Cetuximab than the patients that expressed low Tspan6 levels. These results identify Tspan6 as a regulator of CRC development and a potential predictive marker for EGFR-targeted therapies in CRC beyond RAS pathway mutations.
登录
查看更多内容
影响因子:
15.1
作者:
Guix FX;Sannerud R;Berditchevski F;Arranz AM;Horré K;Snellinx A;Thathiah A;Saido T;Saito T;Rajesh S;Overduin M;Kumar-Singh S;Radaelli E;Corthout N;Colombelli J;Tosi S;Munck S;Salas IH;Annaert W;De Strooper B
通讯作者:
De Strooper B
影响因子:
11.2
作者:
Greco, Celine;Bralet, Marie-Pierre;Boucheix, Claude
通讯作者:
Boucheix, Claude
影响因子:
3.9
作者:
Latifkar A;Cerione RA;Antonyak MA
通讯作者:
Antonyak MA
影响因子:
29.4
作者:
Srivatsa S;Paul MC;Cardone C;Holcmann M;Amberg N;Pathria P;Diamanti MA;Linder M;Timelthaler G;Dienes HP;Kenner L;Wrba F;Prager GW;Rose-John S;Eferl R;Liguori G;Botti G;Martinelli E;Greten FR;Ciardiello F;Sibilia M
通讯作者:
Sibilia M
DOI:
10.1073/pnas.1922447117
发表时间:
2020-03-17
影响因子:
11.1
作者:
Ghossoub, Rania;Chery, Marion;Zimmermann, Pascale
通讯作者:
Zimmermann, Pascale